Inergetics Inc (fka NRTI)

[crookedneck]

NRTI will set the drug to market in spectacular fashion. They plan is to host a media event in New York City. Attendees will include shareholders, media and members of the investment community. The date of the event will be released as the product nears the completion of the final testing phase. The product is an important addition to the company’s portfolio. It will be its first exposure to the medical marijuana marketplace, a billion dollar industry even in its youth.

That is a quote from the MMJ Observer this morning. They changed the timing of the event from their earlier quote a day ago where they said "by the end of February" to "The date of the event will be released as the product nears the completion of the final testing phase". But it could be a clue to the end of February as being the launch date. Mr. James is not one to give an exact timing, unless he is 100% sure. Probably the reason he said "before the end of the 1st qtr".

However, the article makes it clear that it will be HUGE event with plenty of press and investors! They are going to really knock this out of the park with this launch! Cheers!

Intergetics Inc (OTCMKTS:NRTI) Prepares Cannabidoil Pain Reliver For Marketing
February 6, 2015 by Steven Goodstein No Comments
Intergetics Inc (OTCMKTS:NRTI) has moved its cannabidiol (CBD) pain reliever to the final phase in testing and will prepare to market it for release to consumers. The company is respected ass a leader in the nutritional marketplace and this entry solves some very serious concerns for patients in pain. The company had meetings with the CBD initiative Scientific/Medical Advisory Board last year to find out the CBD drug is making great progress in testing. Details must be worked out before the drug can be marketed. Dosage amounts, brand name, product identity and regulatory concerns must be cleared before any marketing efforts can begin. The product is scheduled for launch during the first quarter of this year.

Gala Event

Intergetics Inc (OTCMKTS:NRTI) will set the drug to market in spectacular fashion. They plan is to host a media event in New York City. Attendees will include shareholders, media and members of the investment community. The date of the event will be released as the product nears the completion of the final testing phase. The product is an important addition to the company’s portfolio. It will be its firstexposure to the medical marijuana marketplace, a billion dollar industry even in its youth.

Safer Than Opiates

Pain medicine is a huge part of the prescription drug marketplace. Almost a third of its sales come from pain prescriptions and over the counter products. But these are too often opiate based drugs and subject the patient to many risks and side effects. The biggest risk is addiction. Every year thousands of patients in pain succumb to the addicting effects of opiate based pain medications. There are also devastating side effects associated with them. Nausea is the most common. CBD based pain relievers do not expose users to the same risks and are an exciting alternative for patients.

Technical

The news of the new CBD pain reliever caused intense volume to come into the stock and it doubled quickly. This is before it has been marketed. The stock is still extremely undervalued and has the potential to challenge its 52-week high soon.

http://www.mmjobserver.com/intergetics-inc-otcmktsnrti-prepares-cannabidoil-pain-reliver-for-marketing/3993/